The effectiveness of Ibuprofen and Lorazepam combination therapy in treating the symptoms of acute migraine

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20160927003

Enrollment

Unknown

Registered

2016-09-27

Start date

2014-09-04

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ethics Committee Branch of Tonekabon Islamic Azad University has approved the study design. Participation in the study is voluntary. Each of the study participants were able to recognize and feel them Migraine&#44

Interventions

The present quasi&#45

experimental study used the pretest&#45

posttest design with three comparison treatments to examine 90 patients with an average of two to six attacks per month and an initial diagnosis of migraine based on the International Headache Society

the second group 400 mg Ibuprofen capsules and the third group a combination of 200 mg Ibuprofen capsules and 1 mg Lorazepam tablets. The medications were taken in the presence of the researcher. A ch

vomiting&#44

photophobia and phonophobia in the patients before and two hours after the intervention,the second group 400 mg Ibuprofen capsules,the third group a combination of 200 mg Ibuprofen capsules and 1 mg L

Experimental Drug,Experimental Drug,Experimental Drug

The first group was administered 200 mg Ibuprofen capsules ,400 mg Ibuprofen capsules,a combination of 200 mg Ibuprofen capsules and 1 mg Lorazepam tablets

Eligibility

Sex/Gender

All

Age

52 Years to 60 Years

Inclusion criteria

Inclusion criteria: patients with an average of two to six attacks per month and an initial diagnosis of migraine based on the International Headache Society (HIS) criteria were selected through convenience sampling

Exclusion criteria

Exclusion criteria: patients that was diagnosed of migraine absolutely

Design outcomes

Primary

Measure	Time frame
Migraine at 3 months after end of the intervention The International Headache Societyâ€™s Scale, Migraine at 3 months after end of the intervention The International Headache Societyâ€™s Scale	—

Secondary

Measure	Time frame
nausea and vomiting at 3 months after end of the intervention Patient reported outcome using a questionnaire interview	—

Contacts

Public Contactzahra fotoukian

Assistant Professor, Ramsar Nursing and Midwifery School, Babol Medical Sciences University, Babol,

zfotoukian@yahoo.com+989127177552

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026